Table 1. Clinical characteristics of 1770 patients with NSCLC.

	Adenocarcinoma		Adenosquamous carcinoma		Squamous cell carcinoma
	No.	%	No.	%	No.	%
Total	1305		48		417
Sex
Male	573	43.9%	34	70.8%	384	92.1%
Female	732	56.1%	14	29.2%	33	7.9%
Age
> 60 y	657	50.3%	29	60.4%	228	54.7%
< 60 y	648	49.7%	19	39.6%	189	45.3%
Smoking status
Smoker	401	30.7%	27	56.3%	351	84.2%
Never-smoker	904	69.3%	21	43.8%	66	15.8%
Pathologic stage
0	32	2.5%	0	0.0%	0	0.0%
IA	510	39.1%	7	14.6%	70	16.8%
IB	171	13.1%	11	22.9%	104	24.9%
IIA	113	8.7%	3	6.3%	65	15.6%
IIB	43	3.3%	5	10.4%	47	11.3%
IIIA	352	27.0%	21	43.8%	125	30.0%
IIIB	30	2.3%	1	2.1%	4	1.0%
IV	54	4.1%	0	0.0%	2	0.5%
Differentiation
Well	197	15.1%	0	0.0%	8	1.9%
Moderate	734	56.2%	16	33.3%	188	45.1%
Poor	374	28.7%	32	66.7%	221	53.0%
EGFR Mutation
Present	855	65.5%	20	41.7%	17	4.1%
Absent	450	34.5%	28	58.3%	400	95.9%
KRAS Mutation
Present	107	8.2%	6	12.5%	6	1.4%
Absent	1198	91.8%	42	87.5%	411	98.6%
HER2 Insertion
Present	32	2.5%	1	2.1%	4	1.0%
Absent	1273	97.5%	47	97.9%	413	99.0%
BRAF Mutation
Present	20	1.5%	0	0.0%	0	0.0%
Absent	1285	98.5%	4	8.3%	417	100.0%
ALK Fusion
Present	70	5.4%	4	8.3%	2	0.5%
Absent	1235	94.6%	44	91.7%	415	99.5%
RET Fusion
Present	18	1.4%	2	4.2%	0	0.0%
Absent	1287	98.6%	46	95.8%	417	100.0%
ROS1 Fusion
Present	11	0.8%	0	0.0%	0	0.0%
Absent	1294	99.2%	48	100.0%	417	100.0%
FGFR1/3 Fusion
Present	6	0.5%	0	0.0%	12	2.9%
Absent	1299	99.5%	48	100.0%	405	97.1%
MET Skipping
Present	21	1.6%	2	4.2%	0	0.0%
Absent	1284	98.4%	46	95.8%	417	100.0%
PIK3CA Mutation
Present	22	1.7%	1	2.4%	12	7.5%
Absent	1270	98.3%	40	97.6%	147	92.5%
CTNNB1 Mutation
Present	32	3.8%	1	2.4%	2	0.5%
Absent	815	96.2%	40	97.6%	371	99.5%